These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26929268)

  • 21. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.
    Misawa K; Nishimura T; Kashimura S; Enoki Y; Taguchi K; Uno S; Uwamino Y; Matsumoto K; Hasegawa N
    Int J Antimicrob Agents; 2022; 60(5-6):106669. PubMed ID: 36064079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of β-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus.
    Dubée V; Soroka D; Cortes M; Lefebvre AL; Gutmann L; Hugonnet JE; Arthur M; Mainardi JL
    Antimicrob Agents Chemother; 2015 May; 59(5):2938-41. PubMed ID: 25733512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the
    Kaushik A; Ammerman NC; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model.
    Molina-Torres CA; Tamez-Peña L; Castro-Garza J; Ocampo-Candiani J; Vera-Cabrera L
    J Microbiol Methods; 2018 May; 148():29-32. PubMed ID: 29626567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
    Gui J; Wang F; Hong CY; Li JL; Liang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Le Run E; Arthur M; Mainardi JL
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745387
    [No Abstract]   [Full Text] [Related]  

  • 29. The addition of avibactam renders piperacillin an effective treatment for
    Meir M; Bifani P; Barkan D
    Antimicrob Resist Infect Control; 2018; 7():151. PubMed ID: 30564307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase.
    Soroka D; Dubée V; Soulier-Escrihuela O; Cuinet G; Hugonnet JE; Gutmann L; Mainardi JL; Arthur M
    J Antimicrob Chemother; 2014 Mar; 69(3):691-6. PubMed ID: 24132992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.
    McLeod SM; Patey SA; Huband MD; Nichols WW
    Int J Antimicrob Agents; 2017 Apr; 49(4):437-442. PubMed ID: 28242258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.
    Ferro BE; van Ingen J; Wattenberg M; van Soolingen D; Mouton JW
    J Antimicrob Chemother; 2015 Mar; 70(3):811-7. PubMed ID: 25344808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
    Sayed ARM; Shah NR; Basso KB; Kamat M; Jiao Y; Moya B; Sutaria DS; Lang Y; Tao X; Liu W; Shin E; Zhou J; Werkman C; Louie A; Drusano GL; Bulitta JB
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106266
    [No Abstract]   [Full Text] [Related]  

  • 35. Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus.
    Lindman M; Dick T
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New β-lactam-β-lactamase inhibitor combinations in clinical development.
    Shlaes DM
    Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex.
    Singh S; Bouzinbi N; Chaturvedi V; Godreuil S; Kremer L
    Clin Microbiol Infect; 2014 Dec; 20(12):O1124-7. PubMed ID: 25185732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.
    Greendyke R; Byrd TF
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2019-26. PubMed ID: 18378709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors and inactivators of beta-lactamase from Mycobacterium fortuitum.
    Fattorini L; Amicosante G; Fiorentino D; Franceschini N; Di Marzio L; Oratore A; Orefici G
    J Chemother; 1989 Oct; 1(5):293-7. PubMed ID: 2585031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.